Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC)
作者:Ya Chen、Yong Tang、Beibei Mao、Wenchao Li、Hongwei Jin、Liangren Zhang、Zhenming Liu
DOI:10.3390/molecules23030678
日期:——
Any type of breast cancer not expressing genes of the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) is referred to as triple-negative breast cancer (TNBC). Accordingly, TNBCs do not respond to hormonal therapies or medicines targeting the ER, PR, or HER2. Systemic chemotherapy is therefore the only treatment option available today and prognoses remain poor. We report the discovery and characterization of N-(naphtho[1,2-b]furan-5-yl)benzenesulfonamides as selective inhibitors of TNBCs. These inhibitors were identified by virtual screening and inhibited different TNBC cell lines with IC50 values of 2–3 μM. The compounds did not inhibit normal (i.e. MCF-7 and MCF-10A) cells in vitro, indicating their selectivity against TNBC cells. Considering the selectivity of these inhibitors for TNBC, these compounds and analogs can serve as a promising starting point for further research on effective TNBC inhibitors.
任何不表达雌激素受体(ER)、孕激素受体(PR)或人表皮生长因子受体 2(HER2)基因的乳腺癌都被称为三阴性乳腺癌(TNBC)。因此,TNBC 对激素疗法或针对 ER、PR 或 HER2 的药物没有反应。因此,全身化疗是目前唯一的治疗方法,而且预后仍然很差。我们报告了作为 TNBC 选择性抑制剂的 N-(萘并[1,2-b]呋喃-5-基)苯磺酰胺的发现和特性。这些抑制剂是通过虚拟筛选确定的,对不同的 TNBC 细胞系均有抑制作用,IC50 值为 2-3 μM。这些化合物在体外对正常细胞(即 MCF-7 和 MCF-10A)没有抑制作用,这表明它们对 TNBC 细胞具有选择性。考虑到这些抑制剂对 TNBC 的选择性,这些化合物及其类似物有望成为进一步研究有效 TNBC 抑制剂的起点。